Could cause temporary or reversible harm; serious harm is unlikely.
Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin
| Brand name | CLARAVIS |
| Generic name | ISOTRETINOIN |
| Active ingredient(s) | ISOTRETINOIN |
| Distributed by / for | Teva Pharmaceuticals USA, Inc |
| NDC | 0555-1054-56 |
| Full product label | Claravis (isotretinoin capsule, USP), 10 mg, Packaged as a) 100-count carton, NDC 0555-1054-56, with 10x10 blister packs NDC 0555-1054-60; b) 30-count carton, NDC 0555-1054-86, with 3X10 blister pack NDC 0555-1054-60; Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454. |
| Recalling firm | Teva Pharmaceuticals USA, Inc |
| Distribution | Nationwide in the USA, Puerto Rico and Virgin Islands |
| Quantity | 5,101 cartons |
| Recall initiated | 2026-04-06 |
| Report date | 2026-04-29 |
| Recall completed | — |
| Recall number | D-0521-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Parsippany NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗